Immunopotentiation in the Presence of Tenofovir-induced Phosphaturia in HIV-infected Patients on TenofovirNumbara Deebii*
Department of Haematology, Blood Transfusion and Immunology, University of Port Harcourt, Rivers State, Nigeria
- *Corresponding Author:
- Deebii Numbara
Department of Haematology, Blood Transfusion and Immunology
University of Port Harcourt, Rivers State, Nigeria
E-mail: [email protected]
Received date: January 13, 2017; Accepted date: February 21, 2017; Published date: February 28, 2017
Citation: Numbara D (2017) Immunopotentiation in the Presence of Tenofovir-induced Phosphaturia in HIV-infected Patients on Tenofovir. J Med Diagn Meth 6:238. doi:10.4172/2168-9784.1000238
Copyright: © 2017 Numbara D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Tenofovir disoproxil fumarate (TDF) remains the most widely use and prescribed first line antiretroviral therapy in the treatment of patients infected HIV-infection but unfortunately it is possibly nephrotoxic especially on the kidney tubules. In this longitudinal study we evaluated the influence of TDF on the renal tubules, measuring urinary phosphate and protein. 57 patients infected with HIV were recruited and grouped as follows: TDF group (21 patients), Non-TDF group (21 patients) and treatment naïve group (15 patients). Indicators of renal tubular injuriousness together with other common biomarkers of renal injury were evaluated. Phosphaturia was defined as urinary phosphate 20.0 mg/dl and the prevalence of phosphaturia after 12 weeks of follow-up were as follows: TDF group (8), Non-TDF group (1) and treatment naïve group (3). Proteinuria was defined as positive protein on dip stick urine and the prevalence among the different ART regimen groups after 12 weeks were as follows: TDF group (4), Non-TDF group (1) and treatment naïve group (1). CD4 count for the different regimen groups after 12 weeks were as follows: TDF (659.95 ul/cells/<50 copies/ml), non-TDF (363.24 ul/cells/<500 copies/ml) and treatment naïve (276.63 ul/cells/<1000 copies/ml). This higher incidence in phosphaturia and proteinuria in the presence of increased CD4 counts in HIV patients exposed to TDF is believed to be progressive and may subsequently result in a generalized renal tubular toxicity before any rise in serum creatinine.